Rise Nano Optics Announces Strategic Partnership with Sierra Optical Lab to Produce and Commercialize SpectraGuard™ Lenses in the United States
Rise Nano Optics Announces Strategic Partnership with Sierra Optical [...]
Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD™ Nano-Optic Lens Technology
Rise Nano Optics Announces FDA Class I Device Classification [...]
Rise Nano Optics Appoints Erik Ritchie as Chief Commercial Officer to Lead North American Commercialization Strategy
Rise Nano Optics Appoints Erik Ritchie as Chief Commercial [...]
Rise Nano Optics to Commence Trading on the Canadian Securities Exchange Under The Symbol “EYE”, Today, March 12, 2026
Rise Nano Optics to Commence Trading on the Canadian [...]
Rise Nano Optics Receives Final Receipt for Prospectus and Closes RTO Transaction
Rise Nano Optics Receives Final Receipt for Prospectus and Closes [...]
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough [...]
Rise Health Nano Optics Achieves FDA Clearance Milestone Following Successful Biocompatibility Testing for EYEGUARD™ Lenses
Rise Health Nano Optics Achieves FDA Clearance Milestone Following Successful [...]
Rise Nano Optics Announces Breakthrough in Nanomaterials Driving Major Production Efficiency Gains
Rise Nano Optics Announces Breakthrough in Nanomaterials Driving Major Production [...]
Rise Health Nano Optics Provides Corporate Update on FDA Approval Process and Product Development Milestones
Rise Health Nano Optics Provides Corporate Update on FDA [...]